205 related articles for article (PubMed ID: 34428596)
21. Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study.
Karaiskos I; Daikos GL; Gkoufa A; Adamis G; Stefos A; Symbardi S; Chrysos G; Filiou E; Basoulis D; Mouloudi E; Galani L; Akinosoglou K; Arvaniti K; Masgala A; Petraki M; Papadimitriou E; Galani I; Poulakou G; Routsi C; Giamarellou H;
J Antimicrob Chemother; 2021 Feb; 76(3):775-783. PubMed ID: 33249436
[TBL] [Abstract][Full Text] [Related]
22. Ceftazidime-Avibactam Resistance Associated with Increased
Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
[TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB
J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
[TBL] [Abstract][Full Text] [Related]
24. Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.
Carattoli A; Arcari G; Bibbolino G; Sacco F; Tomolillo D; Di Lella FM; Trancassini M; Faino L; Venditti M; Antonelli G; Raponi G
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0057421. PubMed ID: 34339281
[TBL] [Abstract][Full Text] [Related]
25. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
[TBL] [Abstract][Full Text] [Related]
26. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
[TBL] [Abstract][Full Text] [Related]
27. Dynamic evolution of ceftazidime-avibactam resistance due to interchanges between
Chen Y; Yang R; Guo P; Liu P; Deng J; Wu Z; Wu Q; Huang J; Liao K
Front Cell Infect Microbiol; 2023; 13():1244511. PubMed ID: 37671146
[TBL] [Abstract][Full Text] [Related]
28. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
29. Detecting KPC-2 and NDM-1 Coexpression in Klebsiella pneumoniae Complex from Human and Animal Hosts in South America.
Vásquez-Ponce F; Dantas K; Becerra J; Melocco G; Esposito F; Cardoso B; Rodrigues L; Lima K; de Lima AV; Sellera FP; Mattos R; Trevisoli L; Vianello MA; Sincero T; Di Conza J; Vespero E; Gutkind G; Sampaio J; Lincopan N
Microbiol Spectr; 2022 Oct; 10(5):e0115922. PubMed ID: 35980188
[TBL] [Abstract][Full Text] [Related]
30. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
[TBL] [Abstract][Full Text] [Related]
31. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
[TBL] [Abstract][Full Text] [Related]
32. KPC-producing Klebsiella pneumoniae gut decolonisation following ceftazidime/avibactam-based combination therapy: A retrospective observational study.
Bassetti M; Carannante N; Pallotto C; Righi E; Di Caprio G; Bernardo M; Sodano G; Mallardo E; Francisci D; Sartor A; Graziano E; Tascini C
J Glob Antimicrob Resist; 2019 Jun; 17():109-111. PubMed ID: 30468915
[TBL] [Abstract][Full Text] [Related]
33. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
[TBL] [Abstract][Full Text] [Related]
35. Meropenem/vaborbactam activity
Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
[TBL] [Abstract][Full Text] [Related]
36. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
Antinori E; Unali I; Bertoncelli A; Mazzariol A
Clin Microbiol Infect; 2020 Jul; 26(7):946.e1-946.e3. PubMed ID: 32061796
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology of resistance of carbapenemase-producing Klebsiella pneumoniae to ceftazidime-avibactam in a Chinese hospital.
Chen D; Xiao L; Hong D; Zhao Y; Hu X; Shi S; Chen F
J Appl Microbiol; 2022 Jan; 132(1):237-243. PubMed ID: 34053144
[TBL] [Abstract][Full Text] [Related]
38. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
Tam VH; Merlau PR; Hudson CS; Kline EG; Eales BM; Smith J; Sofjan AK; Shields RK
J Antimicrob Chemother; 2022 Oct; 77(11):3130-3137. PubMed ID: 36031868
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).
Boattini M; Bianco G; Bastos P; Comini S; Corcione S; Almeida A; Costa C; De Rosa FG; Cavallo R
Eur J Clin Microbiol Infect Dis; 2024 Jan; 43(1):155-166. PubMed ID: 37985552
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
Sader HS; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
